Background: Plasma phosphorylated tau (p-tau) isoforms are established biomarkers of Alzheimer’s disease (AD), but whether their combined elevation reflects biological heterogeneity within AD remains unclear.Objective: To determine whether distinct plasma p-tau217, p-tau181, and p-tau231 profiles identify clinically and biologically meaningful severity strata within biologically confirmed AD.Methods: We included 106 patients with CSF-confirmed AD at the mild cognitive impairment or dementia stage. Participants underwent clinical assessment, CSF Aβ42 and tau biomarker measurement, and plasma assessment of p-tau217, p-tau181, p-tau231, Aβ42/Aβ40, GFAP, and NfL. Longitudinal MMSE data were available in 80 participants over a mean 2.6-year follow-up. Patients were classified using ROC-derived multi-isoform profiles and, separately, p-tau217 quintiles. Clinical and biological group differences and age- and sex-adjusted regression models were evaluated.Results: Multi-isoform profiling identified five profiles, ranging from all-intermediate p-tau isoforms to triple-high. Compared with the all-intermediate profile, profiles with broader p-tau isoform elevation showed higher CSF tau markers, higher plasma GFAP and NfL, and faster annualized MMSE decline. The triple-high profile showed worst cognitive performance and highest plasma biomarker burden. Complementary p-tau217 quintile stratification showed a parallel severity gradient, with higher quintiles associated with increased CSF tau markers, GFAP, NfL, and cognitive decline. Regression analyses supported p-tau217 as the strongest single-marker correlate, whereas p-tau231 contributed to NfL and CSF t-tau models.Conclusions: Multi-isoform plasma p-tau profiling identifies biologically distinct AD severity strata, consistent with a hierarchy of increasing tau phosphorylation burden. p-tau217 captures much of this continuum and remains the most robust single-marker correlate, whereas p-tau231 may provide complementary information on neurodegeneration-related biology.